Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: Results of a double-blind, adjuvant controlled trial

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 10, Issue SUPPL. 2, 1995, Pages

  Trauger, R J ^a   Daigle, A E ^a   Giermakowska, W ^a   Moss, R B ^a   Jensen, F ^a   Carlo, D J ^a  

^a Orchestra Therapeutics Inc   (United States)

Author keywords

Human immunodeficiency virus type 1 immunogen; Immunogenicity; Immunotherapy; Safety

Indexed keywords

GLYCOPROTEIN GP 120; VIRUS ANTIGEN;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOTHERAPY; PRIORITY JOURNAL;

AIDS VACCINES; ANTIGENS, VIRAL; COHORT STUDIES; DOUBLE-BLIND METHOD; FREUND'S ADJUVANT; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; VACCINES, INACTIVATED;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0028827186     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)